Anti-PiLRA Antibodies, Uses Thereof, and Related Methods and Reagents
Summary
Denali Therapeutics Inc. filed patent application 18714069 on December 16, 2022, published as US20260109763A1 on April 23, 2026, covering anti-PILRA antibodies with selectivity profiles allowing comparable binding to cynomolgus and human PILRA proteins while exhibiting much weaker binding to human PILRB protein. The antibodies bind both PILRA G78 and R78 variants and may be used in animal studies without surrogate molecules and for treating subjects with either PILRA variant. This is a standard USPTO patent application publication and does not create compliance obligations.
“Provided herein are anti-PILRA antibodies with the highly desirable selectivity: having comparable binding to cynomolgus and human PILRA proteins, but much weaker binding to human PILRB protein, as well as binding to both PILRA G78 and R78 variants.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
Denali Therapeutics Inc. published patent application US20260109763A1 covering anti-PILRA antibodies with highly selective binding profiles for cynomolgus and human PILRA proteins while demonstrating much weaker binding to human PILRB. The antibodies bind both PILRA G78 and R78 variants and enable animal studies without surrogate molecules.
Pharmaceutical and biotechnology companies developing antibody-based therapeutics targeting neurological conditions should monitor this intellectual property filing. The patent claims establish protection around a specific antibody selectivity profile that could affect competitive development in the PILRA-targeted antibody space. This is a standard USPTO patent application publication with no immediate compliance obligations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-PILRA ANTIBODIES, USES THEREOF, AND RELATED METHODS AND REAGENTS
Application US20260109763A1 Kind: A1 Apr 23, 2026
Assignee
DENALI THERAPEUTICS INC.
Inventors
Claire Da Roza, Do Jin Kim, Kathleen Lisaingo, Madeline MacDonald, Kathryn M. Monroe, Joshua I. Park, Nicholas E. Propson, Hanna Sabelström, Richard Théolis, JR., Tanya N. Weerakkody, Alexander Yang
Abstract
Provided herein are anti-PILRA antibodies with the highly desirable selectivity: having comparable binding to cynomolgus and human PILRA proteins, but much weaker binding to human PILRB protein, as well as binding to both PILRA G78 and R78 variants. The binding and selectivity profiles of the antibodies described herein allow for them to be used in animal studies (e.g., monkeys) without the need to rely on a surrogate molecule and also when treating subjects with either PILRA variant. Further described herein, for the first time, are biological discoveries related to PILRA and the effects of reducing PILRA signaling in cells.
CPC Classifications
C07K 16/2803 A61P 25/28 A61K 2039/505 C07K 2317/52 C07K 2317/565 C07K 2317/76 C07K 2317/92
Filing Date
2022-12-16
Application No.
18714069
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.